Stock STRO SUTRO BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
3.42 USD 0.00% Intraday chart for Sutro Biopharma, Inc. -5.79% -20.28%
03/04 Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating MT
03/04 Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating MT

Business Summary

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.

Number of employees: 302

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceutical Products
100.0 %
68 100.0 % 154 100.0 % +126.84%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
68 100.0 % 154 100.0 % +126.84%

Managers

Managers TitleAgeSince
William Newell CEO
 Chief Executive Officer 66 14/09/14
Jane Chung PSD
 President 53 09/21/09
Edward Albini DFI
 Director of Finance/CFO 66 31/13/31
Steve Michel CTO
 Chief Tech/Sci/R&D Officer - -
Craig Berman CTO
 Chief Tech/Sci/R&D Officer - 21/20/21
Hans-Peter Gerber CTO
 Chief Tech/Sci/R&D Officer - 18/23/18
Henry Heinsohn CTO
 Chief Tech/Sci/R&D Officer - -
Anne Borgman CTO
 Chief Tech/Sci/R&D Officer 56 28/23/28
Linda Fitzpatrick IRO
 Public Communications Contact 67 01/08/01
Werner Rubas PRN
 Corporate Officer/Principal - 16/21/16

Members of the board

Members of the board TitleAgeSince
Connie Matsui CHM
 Chairman 70 24/19/24
James Panek BRD
 Director/Board Member 71 07/20/07
Daniel Petree BRD
 Director/Board Member 68 -
John Freund BRD
 Director/Board Member 70 01/14/01
Joseph Lobacki BRD
 Director/Board Member 65 01/17/01
William Newell CEO
 Chief Executive Officer 66 14/09/14
Michael Dybbs BRD
 Director/Board Member 49 25/18/25
Heidi Hunter BRD
 Director/Board Member 66 19/21/19
Jon Wigginton BRD
 Director/Board Member 62 30/20/30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 75,488,593 74,756,129 ( 99.03 %) 0 99.03 %

Shareholders

NameEquities%Valuation
Point72 Asset Management LP
9.501 %
5,932,908 9.501 % 34 M $
Suvretta Capital Management LLC
9.254 %
5,778,188 9.254 % 33 M $
BlackRock Advisors LLC
8.800 %
5,494,911 8.800 % 31 M $
Adage Capital Partners GP LLC
7.155 %
4,467,796 7.155 % 25 M $
Millennium Management LLC
5.528 %
3,451,825 5.528 % 20 M $
BVF, Inc.
5.362 %
3,347,946 5.362 % 19 M $
Rubric Capital Management LP
5.357 %
3,344,810 5.357 % 19 M $
Vanguard Fiduciary Trust Co.
4.628 %
2,890,000 4.628 % 16 M $
Fiduciary Trust Company International
4.424 %
2,762,636 4.424 % 16 M $
Kynam Capital Management LP
3.206 %
2,001,727 3.206 % 11 M $

Company contact information

Sutro Biopharma, Inc.

111 Oyster Point Boulevard

94080, South San Francisco

+650 881 6500

http://www.sutrobio.com
address Sutro Biopharma, Inc.(STRO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Sutro Biopharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.42 USD
Average target price
12.89 USD
Spread / Average Target
+276.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SUTRO BIOPHARMA, INC. Stock Sutro Biopharma, Inc.
-20.28% 263M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. STRO Stock
  4. Company Sutro Biopharma, Inc.